|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1098.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 42.84 | 70.80 | 58.46 | 48.00 | 52.74 | CEPS(Rs) | 49.36 | 76.46 | 63.80 | 52.91 | 56.51 | DPS(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.00 | Book NAV/Share(Rs) | 633.48 | 593.12 | 524.29 | 468.25 | 422.85 | Tax Rate(%) | 23.10 | 14.53 | 15.14 | 11.74 | 18.14 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 16.04 | 18.77 | 22.70 | 19.43 | 21.05 | EBIT Margin(%) | 19.37 | 28.61 | 26.53 | 26.68 | 32.39 | Pre Tax Margin(%) | 17.12 | 25.98 | 23.34 | 22.86 | 28.84 | PAT Margin (%) | 13.16 | 22.21 | 19.80 | 20.18 | 23.61 | Cash Profit Margin (%) | 15.17 | 23.98 | 21.61 | 22.24 | 25.29 | Performance Ratios | | | | | | ROA(%) | 4.60 | 8.22 | 7.72 | 7.49 | 9.59 | ROE(%) | 6.98 | 12.67 | 11.78 | 10.77 | 13.34 | ROCE(%) | 8.58 | 13.25 | 12.54 | 11.24 | 14.36 | Asset Turnover(x) | 0.35 | 0.37 | 0.39 | 0.37 | 0.41 | Sales/Fixed Asset(x) | 2.96 | 3.06 | 3.06 | 2.77 | 2.60 | Working Capital/Sales(x) | 12.35 | 9.35 | 3.46 | 3.30 | 2.20 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.34 | 0.33 | 0.33 | 0.36 | 0.38 | Receivable days | 103.04 | 104.82 | 94.75 | 106.64 | 171.25 | Inventory Days | 40.58 | 34.77 | 35.06 | 47.54 | 58.54 | Payable days | 221.36 | 190.67 | 198.46 | 226.78 | 254.34 | Valuation Parameters | | | | | | PER(x) | 10.85 | 6.25 | 7.95 | 4.29 | 12.24 | PCE(x) | 9.42 | 5.78 | 7.28 | 3.89 | 11.42 | Price/Book(x) | 0.73 | 0.75 | 0.89 | 0.44 | 1.53 | Yield(%) | 0.54 | 0.57 | 0.54 | 1.21 | 0.31 | EV/Net Sales(x) | 1.97 | 1.98 | 2.21 | 1.39 | 3.35 | EV/Core EBITDA(x) | 6.58 | 7.00 | 7.31 | 4.87 | 11.70 | EV/EBIT(x) | 9.10 | 6.26 | 7.57 | 5.19 | 10.33 | EV/CE(x) | 0.60 | 0.63 | 0.73 | 0.47 | 1.28 | M Cap / Sales | 1.60 | 1.53 | 1.73 | 0.87 | 2.89 | Growth Ratio | | | | | | Net Sales Growth(%) | 0.97 | 7.58 | 12.74 | 6.47 | 14.21 | Core EBITDA Growth(%) | 6.77 | 0.71 | 19.65 | 5.99 | 40.76 | EBIT Growth(%) | -30.88 | 16.47 | 23.37 | -12.29 | 72.31 | PAT Growth(%) | -39.49 | 21.12 | 21.77 | -8.99 | 71.89 | EPS Growth(%) | -39.49 | 21.12 | 21.77 | -8.99 | 71.89 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.18 | 0.22 | 0.25 | 0.27 | 0.26 | Current Ratio(x) | 1.15 | 1.20 | 1.61 | 1.68 | 2.25 | Quick Ratio(x) | 0.93 | 1.00 | 1.42 | 1.40 | 1.85 | Interest Cover(x) | 8.60 | 10.90 | 8.31 | 6.99 | 9.12 | Total Debt/Mcap(x) | 0.24 | 0.29 | 0.28 | 0.61 | 0.17 |
|
|
|
|
|
|